Treatment Considerations for Anxiety in the Elderly

CNS Spectrums

Volumn 8, Issue 12 SUPPL. 3, 2003, Pages 6-13

  Lenze, Eric J ^a   Pollock, Bruce G ^b   Shear, M Katherine ^b   Mulsant, Benoit H ^b   Bharucha, Ashok ^b   Reynolds III, Charles F ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABECARNIL; ALPIDEM; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHOLINESTERASE INHIBITOR; CITALOPRAM; FLUVOXAMINE; GABAPENTIN; KETAZOLAM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXAZEPAM; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VENLAFAXINE;

AGED; ANTICHOLINERGIC EFFECT; ANXIETY; ANXIETY DISORDER; BEHAVIOR THERAPY; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; ELDERLY CARE; FALLING; FRACTURE; HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYMPTOMATOLOGY; SYNDROME DELINEATION;

EID: 1642460961     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900008221     Document Type: Review

References (75)

1. de Beurs E, Beekman A, Geerlings S, Deeg D, Van Dyck R, van Tilburg W. On becoming depressed or anxious in late life: similar vulnerability factors but different effects of stressful life events. Br J Psychiatry. 2001;179:426-431.
2. Harman JS, Rollman BL, Hanusa BH, Lenze EJ, Shear MK. Physician office visits of adults for anxiety disorders in the United States: 1985-1998. J Gen Intern Med. 2002;17:165-172.
3. Gleason PP, Schulz R, Smith NL, et al. Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Intern Med. 1998;13:243-250.
4. van Balkom AJ, Beekman AT, de Beurs E, Deeg DJ, Van Dyck R, van Tilburg W. Comorbidity of the anxiety disorders in a community-based older population in The Netherlands. Acta Psychiatr Scand. 2000;101:37-45.
5. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avom J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry. 2001;158:892-898.
6. Cumming R, Le Couteur D. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs. 2003;17:825-837.
7. Pomara N, Tun H, DaSilva D, Hernando R, Deptula D, Greenblatt DJ. The acute and chronic performance effects of alprazolam and lorazepam in the elderly: relationship to duration of treatment and self-rated sedation. Psychopharmacol Bull. 1998;34:139-153.
8. Pomara N, Deptula D, Medel M, Block RI, Greenblatt DJ. Effects of diazepam on recall memory: relationship to aging, dose, and duration of treatment. Psychopharmacol Bull. 1989;25:144-148.
9. Hanlon JT, Horner RD, Schmader KE, et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther. 1998;64:684-692.
10. Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: The epidemiology of vascular aging study. J Clin Psychopharmacol. 2002;22:285-293.
11. Beekman AT, Bremmer MA, Deeg DJ, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry. 1998;13:717-726.
12. Manela M, Katona C, Livingston G. How common are the anxiety disorders in old age? Int J Geriatr Psychiatry. 1996;11:65-70.
13. Lindesay J, Briggs K, Murphy E. The Guy's/Age Concern survey. Prevalence rates of cognitive impairment, depression and anxiety in an urban elderly community. Br J Psychiatry. 1989;155:317-329.
14. Uhlenhuth EH, Balter MB, Mellinger GD, Cisin IH, Clinthorne J. Symptom checklist syndromes in the general population. Correlations with psychotherapeutic drug use. Arch Gen Psychiatry. 1983;40:1167-1173.
15. Carter RM, Wittchen HU, Pfister H, Kessler RC. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety diorder in a nationally representative sample. Depress Anxiety. 2001;13:78-88.
16. Xavier FM, Ferraz MP, Trenti CM, et al. Generalized anxiety disorder in a population aged 80 years and older. Rev Saude Publica. 2001;35:294-302.
17. Blazer D. The epidemiology of anxiety disorders: An age comparison. In: Salzman C, Lebowitz B, eds. Anxiety in the Elderly. New York, NY: Springer Publishing Co.; 1991:17-30.
18. Mohlman J, Gorenstein EE, Kleber M, de Jesus M, Gorman JM, Papp LA. Standard and enhanced cognitive-behavioral therapy for late-life generalized anxiety disorder. Am J Geriatr Psychiatry. 2003;11:24-32.
19. Stanley MA, Beck JG, Novy DM, et al. Cognitive-behavioral treatment of late-life generalized anxiety disorder. J Consult Clin Psychol. 2003;71:309-319.
20. Koepke HH, Gold RL, Linden ME, Lion JR, Rickels K. Multicenter controlled study of oxazepam in anxious elderly outpatients. Psychosomatics. 1982;23:641-645.
21. Bresolin N, Monza G, Scarpini E, et al. Treatment of anxiety with ketazolam in elderly patients. Clin Ther. 1988;10:536-542.
22. Frattola L, Piolti R, Bassi S, Albizzati MG, et al. Effects of alpidem in anxious elderly outpatients: A double-blind, placebo-controlled trial. Clin Neuropharmacol. 1992;15:477-487.
23. Small GW, Bystritsky A. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety. J Clin Psychiatry. 1997;58:24-29.
24. Stanley MA. Treatment of generalized anxiety in older adults: A preliminary comparison of cognitive-behavioral and supportive approaches. Behav Ther. 1996;27:565-581.
25. Stanley MA, Hopko DR, Diefenbach GJ, Bourland SL, Rodriguez H, Wagener P. Cognitive-behavioral therapy for late-life generalized anxiety disorder in primary care: Priliminary findings. Am J Geriatr Psychiatry. 2003;11:92-96.
26. Wetherell JL, Gatz M. Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychology. 2003;71:31-40.
27. Hemmelgarn B, Suissa S, Huang A, Boivin J-F, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278:27-31.
28. Herings RMC, Stricker BHC, deBoer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. Arch Intern Med. 1995;155:1801-1807.
29. Liu BA, Topper AK, Reeves RA, Gryfe C, Maki BE. Falls among older people: relationship to medication use and orthostatic hypotension. J Am Geriatr Soc. 1995;43:1141-1145.
30. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989;262:3303-3307.
31. Salzman C, Fisher J, Nobel K, Glassman R, Wolfson A, Kelley M. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry. 1992;7:89-93.
32. Salzman C. Anxiety in the elderly: treatment strategies. J Clin Psychiatry. 1999;51:18-21.
33. Dada F, Sethi S, Grosberg GT. Generalized anxiety disorder in the elderly. Psychiatr Clin North Am. 2001;1:164.
34. Pollock B, Mulsant BH. Psychopharmacology. In: Crome P, Ford G, eds. Drugs and the Older Population. London, England: Imperial College Press; 2000:275-303.
35. Katz IR, Reynolds CF, Alexopoulos GS, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc. 2002;50:18-24.
36. Manela M, Katona C, Livingston G. How common are the anxiety disorders in old age? Int J Geriatr Psychiatry. 1996;11:65-70.
37. Regier DA, Boyd JH, Burke JD, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988;45:977-986.
38. Beekman A, Bremmer MA, Deeg D et al. Anxiety disorders in later life: A report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry. 1998;13:717-726.
39. Flint AJ, Cook JM, Rabins PV. Why is panic disorder less frequent in late life? Am J Geriatr Psychiatry. 1996;4:96,109.
40. Flint AJ, Koszycki D, Vaccarino FJ, Cadieux A, Boulenger JP, Bradwejn J. Effect of aging on cholecystokinin-induced panic. Am J Psychiatry. 1998;155:283-285.
41. Lenze EJ, Mulsant BH, Shear MK et al. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry. 2000;157:722-728.
42. Brown C, Schulberg HC, Madonia M, Shear MK, Houck P. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry. 1996;153:1293-1300.
43. Palmer BW, Jeste DV, Sheikh JI. Anxiety disorders in the elderly: DSM-IV and other barriers to diagnosis and treatment. J Affect Disord. 1997;46:183-190.
44. Davidson JR, Hughes D, Blazer DG, George LK. Post-traumatic stress disorder in the community: an epidemiological study. Psychol Med. 1991;21:713-721.
45. Goenjian AK, Najarian LM, Pynoos RS et al. Posttraumatic stress disorder in elderly and younger adults after the 1988 earthquake in Armenia. Am J Psychiatry. 1994;151:895-901.
46. Madakasira S, O'Brien KE Acute posttraumatic stress disorder in victims of a natural disaster. J Nerv Ment Dis. 1987;175:286-290.
47. Sembi S, Tarrier N, O'Neill P, Burns A, Faragher B. Does post-traumatic stress disorder occur after stroke: a preliminary study. Int J Geriatr Psychiatry. 1998;13:315-322.
48. Dew MA, Roth LH, Schulberg HC, et al. Prevalence and predictors of depression and anxiety-retated disorders during the year after heart transplantation. Gen Hosp Psychiatry. 1996;18(suppl):48S-61S.
49. Flint AJ. Management of anxiety in late life. J Geriatr Psychiatry Neurol. 1998;11:194-200.
50. Wylie ME, Miller MD, Shear MK, et al. Fluvoxamine pharmacotherapy of anxiety disorders in later life: Preliminary open-trial data and a review of the literature. J Geriatr Psychiatry Neurol. 2000;13:43-48.
51. Lenze EJ, Fabian T, Kroboth P, et al. Treatment of anxiety disorders in elderly subjects: a controlled study with citalopram. Poster presented at: Annual Meeting of the International College of Geriatric Psychopharmacology; December 2003; San Juan, Puerto Rico.
52. Bohm C, Robinson DS, Gammans RE et al. Buspirone therapy in anxious elderly patients: a controlled clinical trial. J Clin Psychopharmacol. 1990;10:(suppl):S51.
53. Barrowclough C, King P, Colville J, Russell E, Burns A, Tarrier N. A randomized trial of the effectiveness of cognitive-behavioral therapy and supportive counseling for anxiety symptoms in older adults. J Consult Clin Psychology. 2001;69:756-762.
54. Goodnick PJ, Puig A, DeVane CL, Freund BV. Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry. 1999;60:446-448.
55. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001;34:1303-1307.
56. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467-471.
57. Butterfield MI, Becker ME, Connor KM. Olanzapine in the treatment of post-traumatic stress disorder: A pilot study. Clin Psychopharmacol. 2001;16:203.
58. Kaplan M. Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry. 2000;61:389.
59. Bartels SJ, Coakley E, Oxman TE, et al. Suicidal and death ideation in older primary care patients with depression, anxiety and at-risk alcohol use. Am J Geriatr Psychiatry. 2002;10:417-427.
60. Beekman AT, de Beurs E, van Balkom AJ, Deeg DJ, Van Dyck R, van Tilburg W. Anxiety and depression in later life: co-occurrence and communality of risk factors. Am J Psychiatry. 2000;157:89-95.
61. Mulsant BH, Reynolds CF, Shear MK, Sweet RA, Miller MD. Comorbid anxiety disorders in late-life depression. Anxiety. 1996;2:242-247.
62. Allgulander C, Lavori PW. Causes of death among 936 elderly patients with 'pure' anxiety neurosis in Stockholm County, Sweden, and in patients with depressive neurosis or both diagnoses. Compr Psychiatry. 1993;34:299-302.
63. Flint AJ, Rifat SL. Anxious depression in elderly patients. Response to antidepressant treatment. Am J Geriatr Psychiatry. 1997;5:107-115.
64. Dew MA, Reynolds CF, Houck PR, et al. Temporal profiles of the course of depression during treatment: predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry. 1997;54:1016-1024.
65. Lenze EJ, Mulsant BH, Shear MK, Houck P, Reynolds CE Anxiety symptoms in elderly patients with depression: What is the best approach to treatment? Drugs Aging. 2002;19:753-760.
66. Lenze EJ, Mulsant BH, Dew MA, et al. Good treatment outcomes in late-life depression with comorbid anxiety. J Affect Disord. In press.
67. Buysse DJ, Reynolds CF, Houck PR, et al. Does lorazepam impair the antidepressant response to nortriptyline and psychotherapy? J Clin Psychiatry. 1997;58:426-432.
68. Joo JH, Lenze EJ, Mulsant BH, et al. Risk factors for falls during treatment of late-life depression. J Clin Psychiatry. 2002;63:936-941.
69. Small GW. Recognizing and treating anxiety in the elderly. J Clin Psychiatry. 1997;58:41-47.
70. Kim JM, Lyons D, Shin IS, Yoon JS. Differences in the behavioral and psychological symptoms between Alzheimer's disease and vascular dementia: are the different pharmacologic treatment strategies justifiable? Hum Psychopharmacol. 2003;18:215-220.
71. Mintzer J, Faison W, Street JS, Sutton VK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: A post-hoc analysis. Int J Geriatr Psychiatry. 2001;16(suppl):S71-S77.
72. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence, based recommendations. Am J Geriatr Psychiatry. 2003;11:131-145.
73. Covington JS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: a double-blind comparison of a phenothiazine and a benzodiazepine. South. Med J. 1975;68:719-724.
74. Hughes CM, Lapane KL, Mor V, et at. The impact of legislation on psychotropic drug use in nursing homes: a cross-national perspective. J Am Geriatr Soc. 2000;48:931-937.
75. Miller MD, Frank E, Reynolds CE The art of clinical management in pharmacologic trials with depressed elderly patients: Lessons from the Pittsburgh study of maintenance therapies in late-life depression. Am J Geriatr Psychiatry. 1999;7:228,234.